Table 3:

Pegaspargase allergic reactions

	Cohort	Reaction to rituximab	Phase	Cumulative doses at reaction	Grade	Symptoms	Intervention	Anti-pegaspargase antibodies
Received rituximab	1	Y	Early intensification	3	3	Periorbital edema, abdominal rash, emesis, cough, hypoxia, wheezing	Albuterol, oxygen, diphenhydramine, ranitidine, epinephrine	Positive
	1	Y	Early intensification	3	4	Tachycardia, cyanosis with poor perfusion	Diphenhydramine, oxygen, normal saline boluses, epinephrine	Positive
	2	Y*	Reinduction I	4	2	Facial rash/swelling, intermittent cough	Diphenhydramine	Positive
	2	N	Early intensification	3	3	Lip swelling, emesis, tachycardia, hypotension, somnolence	Ondansetron, methylprednisolone, normal saline boluses, epinephrine	Positive
No rituximab	1	NA	Consolidation	4	2	Emesis, urticaria on neck, arms, and chest	Diphenhydramine, hydrocortisone	Positive
	2	NA	Reinduction I	3	2	Erythema/urticaria, facial edema, cough	Hydrocortisone, epinephrine	Positive
	2	NA	Induction	2	2	Emesis, eyes and lips swelling	Methylprednisolone	Positive
	2	NA	Induction	2	3	Abdominal pain and cramping, emesis, dyspnea	Diphenhydramine, albuterol, oxygen, methylprednisone, ranitidine, epinephrine	Positive
	2	NA	Induction	1	3	Nausea, throat and facial tightness	Oxygen, methylprednisolone	Positive

Abbreviations: PEG, polyethylene glycol; Y, yes; N, no; NA, not applicable

^*Rituximab infusion was not completed due to the reaction.